Low-Dose Subcutaneous Anti-CD20 Treatment Depletes Disease Relevant B Cell Subsets and Attenuates Neuroinflammation

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

Peter McLaughlin, A.J. Grillo-López, Brian K. Link et al. · Journal of Clinical Oncology · 1998 · 2.8K citations

Pharmacy, Hematology, Immunology +17

Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis

John H. Stone, Peter A. Merkel, Robert Spiera et al. · New England Journal of Medicine · 2010 · 2.7K citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

Stephen L. Hauser, Emmanuelle Waubant, Douglas L. Arnold et al. · New England Journal of Medicine · 2008 · 2.4K citations · Full text

Life Sciences, Neurology, Pharmacotherapy +15

Importance of Cellular Microenvironment and Circulatory Dynamics in B Cell Immunotherapy

Qian Gong, Qinglin Ou, Shiming Ye et al. · The Journal of Immunology · 2005 · 540 citations · Full text

Life Sciences, Cell Biology, Immunology +16

Rituximab in relapsing‐remitting multiple sclerosis: A 72‐week, open‐label, phase I trial

Amit Bar‐Or, Peter A. Calabresi, Douglas L. Arnold et al. · Annals of Neurology · 2008 · 530 citations

Pharmacy, Neurology, Pharmacotherapy +13